Скачать или смотреть New Guidelines for Prescribing Sodium Valproate to Men and Women under 55 MHRA

On 31st January 2024, new guidelines from the Medicines and Healthcare Products regulatory Agency came into force for the prescribing of Sodium Valproate to men and women under the age of 55. This is because of the risk of congenital abnormalities of the unborn baby if the mother is taking sodium valproate, and to the risk to a man of becoming less fertile.
A recent study suggested that the children of men who took sodium valproate in the 3 months before their partners became pregnant may be at an increased risk of neurodevelopmental disorders, compared to the children of men taking lamotrigine or levetiracetam (other epileptic drugs).
However, there were flaws in the study, so it is going to be fully reanalysed. As soon as the results of the revised analysis are made available, the MHRA (Medicines and Healthcare Products Regulatory Agency) in the UK will scrutinise these, and if there is further guidance, it will be made available to patients as soon as possible.